EQS-Adhoc: BayWa AG: Impairment tests lead to extraordinary depreciation of € 222.2 million (impairment tests in accordance with IAS 36)

The impairment tests that became necessary led to non-cash impairment losses of
€ 222.2 million, which were recognised as depreciation in the Half-Year Financial Statements 2024. At € 171.5 million, the largest share was attributable to BayWa r.e. AG, a 51% subsidiary of BayWa AG. These depreciations have no negative impact on the BayWa Group’s ongoing restructuring efforts and the implementation of the restructuring concept currently being developed.

The full Half-Year Financial Statements 2024 will be published today on the BayWa Group website.

Contact:

Josko Radeljic, BayWa AG, Head of Investor Relations,
tel. +49 (0)89/92 22-38 87, Fax +49 (0)89/92 12-38 87,
e-mail: [email protected]